CCCC.NASDAQC4 Therapeutics, INC

Form 4: C4 Therapeutics Executive Boyle Exercises Stock Options, Sells Shares for Tax Obligations

Sentiment:

SEC Form 4 Filing

📋All filings for C4 Therapeutics, INC
🔒Login to Follow

C4 Therapeutics' Chief Business Officer, Scott N. Boyle, exercised performance restricted stock units and sold shares to cover tax obligations on November 7, 2024.

Summary

  • On November 7, 2024, Scott N. Boyle, Chief Business Officer of C4 Therapeutics, Inc., exercised 3,750 performance restricted stock units (PRSUs).
  • Following the exercise, Boyle sold 1,102 shares of common stock at $6.04 to satisfy tax withholding obligations.
  • After these transactions, Boyle directly owns 56,567 shares of C4 Therapeutics common stock and 10,500 derivative securities (PRSUs).

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.

Stakeholder Impact

  • The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
  • The filing provides transparency to shareholders regarding insider trading activities.

Key Dates

DateDescription
11/07/2024Date of the earliest transaction: exercise of performance restricted stock units and sale of shares.
11/12/2024Date of signature on the Form 4 filing.
02/28/2025Expiration date of the Performance Restricted Stock Units.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.